At first glance, these results are on par with the recently approved Enhertu.
https://www.daiichisankyo.com/files/news/pressrelease/pdf/202408/20240813_E.pdf
Enhertu
HER-VAXX
However, as has been raised previously, there are concerns with the 80% CI (Vs Enhertu's registrational approval of 95% CI) and the patient randomisation in the HER-VAXX trial. Best case scenario is a third party acquiring the B Cell platform and rerunning this trial. However, pretty risky to expect a more favourable outcome and only 12 years of patent life from today.
(20min delay)